Michael A. James

Michael A. James

Auto-generated profile, based on publicly available information

Michael A. James

Washington University, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MFMatthew L Freedman
Matthew L Freedman
AMAlvaro Monteiro
Alvaro Monteiro
SGSimon A Gayther
Simon A Gayther
GCGerhard A Coetzee
Gerhard A Coetzee
ARAngela Risch
Angela Risch
Ian MillsIan Mills
Ian Mills

27 March 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
STSusan Tsai
Susan Tsai
LMLaura McOlash
Laura McOlash
KPKatie Palen
Katie Palen
BJBryon Johnson
Bryon Johnson
Christine Duris BS HTL(ASCP) QIHC(ASCP)Christine Duris BS HTL(ASCP) QIHC(ASCP)
Christine Duris BS HTL(ASCP) QIHC(ASCP)
MJMichael A. James
Michael A. James
Patient-derived tumor models are the new standard for pre-clinical drug testing and biomarker discovery. However, the emerging technology of primary pancreatic cancer organoids has not yet been broadly implemented in research, and complex organotypic models using organoids in co-culture with stromal and immune cellular components of the tumor have yet to be established. In this study, our objective was to develop and characterize pancreatic cancer organoids and multi-cell type organotypic co-culture models to demonstrate their applicability to the study of pancreatic cancer. We employed organoid culture methods and flow cytometric, cytologic, immunofluorescent and immunohistochemical methods to develop and characterize patient-derived pancreatic cancer organoids and multi-cell type organotypic co-culture models of the tumor microenvironment. We describe the culture and characterization of human pancreatic cancer organoids from resection, ascites and rapid autopsy sources and the derivation of adherent tumor cell monocultures and tumor-associated fibroblasts from these sources. Primary human organoids displayed tumor-like cellular morphology, tissue architecture and polarity in contrast to cell line spheroids, which formed homogenous, non-lumen forming spheres. Importantly, we demonstrate the construction of complex organotypic models of tumor, stromal and immune components of the tumor microenvironment. Activation of myofibroblast-like cancer associated fibroblasts and tumor-dependent lymphocyte infiltration were observed in these models. These studies provide the first report of novel and disease-relevant 3D in-vitro models representing pancreatic tumor, stromal and immune components using primary organoid co-cultures representative of the tumor-microenvironment. These models promise to facilitate the study of tumor-stroma and tumor-immune interaction and may be valuable for the assessment of immunotherapeutics such as checkpoint inhibitors in the context of T-cell infiltration.

17 April 2012 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
PLPengyuan Liu
Pengyuan Liu
CMCarl Morrison
Carl Morrison
LWLiang Wang
Liang Wang
DXDonghai Xiong
Donghai Xiong
PVPeter Vedell
Peter Vedell
MYMing You
Ming You
Lung cancer is the leading cause of cancer-related death, with non-small cell lung cancer (NSCLC) being the predominant form of the disease. Most lung cancer is caused by the accumulation of genomic alterations due to tobacco exposure. To uncover its mutational landscape, we performed whole-exome sequencing in 31 NSCLCs and their matched normal tissue samples. We identified both common and unique mutation spectra and pathway activation in lung adenocarcinomas and squamous cell carcinomas, two major histologies in NSCLC. In addition to identifying previously known lung cancer genes ( TP53 , KRAS , EGFR , CDKN2A and RB1 ), the analysis revealed many genes not previously implicated in this malignancy. Notably, a novel gene CSMD3 was identified as the second most frequently mutated gene (next to TP53 ) in lung cancer. We further demonstrated that loss of CSMD3 results in increased proliferation of airway epithelial cells. The study provides unprecedented insights into mutational processes, cellular pathways and gene networks associated with lung cancer. Of potential immediate clinical relevance, several highly mutated genes identified in our study are promising druggable targets in cancer therapy including ALK, CTNNA3, DCC, MLL3, PCDHIIX, PIK3C2B, PIK3CG and ROCK2 .

4 June 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MJMichael A. James
Michael A. James
WWWeidong Wen
Weidong Wen
YWYian Wang
Yian Wang
LBLauren A. Byers
Lauren A. Byers
JHJohn V. Heymach
John V. Heymach
MYMing You
Ming You
Cleft Lip and Palate Transmembrane Protein 1-Like (CLPTM1L), resides in a region of chromosome 5 for which copy number gain has been found to be the most frequent genetic event in the early stages of non-small cell lung cancer (NSCLC). This locus has been found by multiple genome wide association studies to be associated with lung cancer in both smokers and non-smokers. CLPTM1L has been identified as an overexpressed protein in human ovarian tumor cell lines that are resistant to cisplatin, which is the only insight thus far into the function of CLPTM1L. Here we find CLPTM1L expression to be increased in lung adenocarcinomas compared to matched normal lung tissues and in lung tumor cell lines by mechanisms not exclusive to copy number gain. Upon loss of CLPTM1L accumulation in lung tumor cells, cisplatin and camptothecin induced apoptosis were increased in direct proportion to the level of CLPTM1L knockdown. Bcl-xL accumulation was significantly decreased upon loss of CLPTM1L. Expression of exogenous Bcl-xL abolished sensitization to apoptotic killing with CLPTM1L knockdown. These results demonstrate that CLPTM1L, an overexpressed protein in lung tumor cells, protects from genotoxic stress induced apoptosis through regulation of Bcl-xL. Thus, this study implicates anti-apoptotic CLPTM1L function as a potential mechanism of susceptibility to lung tumorigenesis and resistance to chemotherapy.

15 May 2007 in Cancer Research
Verified
Journal Article
Open access
PDF file
HVHaris Vikis
Haris Vikis
MSMitsuo Sato
Mitsuo Sato
MJMichael James
Michael James
DWDaolong Wang
Daolong Wang
YWYian Wang
Yian Wang
MYMing You
Ming You
The use of tyrosine kinase inhibitors (TKI) has yielded great success in treatment of lung adenocarcinomas. However, patients who develop resistance to TKI treatment often acquire a somatic resistance mutation (T790M) located in the catalytic cleft of the epidermal growth factor receptor (EGFR) enzyme. Recently, a report describing EGFR-T790M as a germ-line mutation suggested that this mutation may be associated with inherited susceptibility to lung cancer. Contrary to previous reports, our analysis indicates that the T790M mutation confers increased Y992 and Y1068 phosphorylation levels. In a human bronchial epithelial cell line, overexpression of EGFR-T790M displayed a growth advantage over wild-type (WT) EGFR. We also screened 237 lung cancer family probands, in addition to 45 bronchoalveolar tumors, and found that none of them contained the EGFR-T790M mutation. Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer. [Cancer Res 2007;67(10):4665–70]

8 November 2010 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
MJMichael A. James
Michael A. James
HFHuijing Fu
Huijing Fu
YLYan Liu
Yan Liu
DCDa‐Ren Chen
Da‐Ren Chen
MYMing You
Ming You